A phaseI/II study of irinotecan with bevacizumab as second line treatment of elderly patients with metastatic colorectal cancer.

ABSTRACT: Interventions: Irinotecan + Bevacizumab Primary outcome(s): Phase I part Estimated the dose limiting toxicities in 1st cycle. Phase II part Progression Free Survival Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2625304 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR